[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-of-liver\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-of-liver":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,95,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":66,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100320510","synergy-ai-artificial-intelligence-based-precision-oncology-clinical-trial-matching-and-registry-100320510",false,"NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\u002FNeu, Tumor mutational burden\u002Fload (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\u002FB, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\u002F2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\u002FB\u002FC, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\u002For patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment","ALL",{"count":17,"type":18},50000,"ESTIMATED","36 Months","OBSERVATIONAL","International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.",[23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65],"Cancer, Metastatic","Cancer","Cancer of Pancreas","Cancer of Liver","Cancer of Stomach","Cancer Liver","Cancer of Rectum","Cancer of Kidney","Cancer of Esophagus","Cancer of Cervix","Cancer of Colon","Cancer of Larynx","Cancer, Lung","Cancer, Breast","Cancer, Advanced","Cancer Prostate","Cancer of Neck","Cancer of Skin","Neuroendocrine Tumors","Carcinoma","Mismatch Repair Deficiency","BRCA Gene Rearrangement","Non Hodgkin Lymphoma","Leukemia","Non Small Cell Lung Cancer","Cholangiocarcinoma","Glioblastoma","Central Nervous System Tumor","Melanoma","Urothelial Carcinoma","Bladder Cancer","Ovarian Cancer","Endometrial Cancer","Testicular Cancer","Breast Cancer","COVID","Myelofibrosis","Myeloproliferative Neoplasm","Myeloproliferative Disorders","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndromes",[67,68,69,70,71,72,73,74,75,76,77,78,79,80,81],"artificial intelligence","virtual tumor board","clinical trial","clinical trial matching","electronic medical record","machine learning","cost of care","targeted therapy","immunotherapy","precision medicine","precision oncology","cancer","value based care","real world data","data analytics","RECRUITING","2025-10-25",{"date":85,"type":86},"2025-10-28","ACTUAL",{"date":88,"type":86},"2018-01-01",{"date":90,"type":18},"2040-06",{"name":92,"class":93},"Massive Bio, Inc.","INDUSTRY",68,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":15,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":122},"100389281","prospective-cohort-of-patients-with-hepatocellular-carcinoma-in-france-100389281","NCT04348838","Prospective Cohort of Patients With Hepatocellular Carcinoma in France","CHIEF","Inclusion Criteria:\n\n* New cases of HCC\n* suspected case of HCC regardless of the cause, stage, treatment\n* Known HCC: drug treatment for recurrence or progression\n\nExclusion Criteria:\n\n* Associated serious condition threatening life in the short term (with the exception of liver disease itself)\n* So-called vulnerable populations: minors, persons under guardianship or temporary guardianship, or person deprived of their liberty by an administrative or judicial decision","18 Years",{"count":104,"type":18},5000,"Hepatocellular carcinoma (HCC) occurs in 90% of cirrhosis primary liver cancers. In France, 8,500 new cases of HCC occur each year, and about 8,000 deaths per year are related to this cancer. The 5-year survival rate is 10%, one of the lowest survival rates of all cancer types. HCC raises a number of major challenges: HCC is discovered at a curable stage in only 25% of cases, reflecting the marked delay in the diagnosis of early stages. The state of knowledge about HCC is well behind that of other cancers (no biomarker, complex carcinogenesis, influence of the aetiology, poorly valorised data, etc.). Rapid technological progress requires large-scale studies to evaluate new diagnostic and therapeutic modalities.\n\nThe CHIEF project constitutes a common basis knowledge for research project using prospectively collected data in patients with HCC, regardless of the cause and stage of the cancer.\n\nThis project is a Multicentre longitudinal observational study of patients with HCC with prospective data collection on inclusion and patient follow-up. Constitution of a biological resources collection. 5,000 patients will be included over 2 years with a follow-up of patients of 5 years.",[26,107],"Hepatocellular Carcinoma",[78,109,110,111],"liver","hepatocellular carcinoma","cohort","2025-06-05",{"date":114,"type":86},"2025-06-10",{"date":116,"type":86},"2019-09-26",{"date":118,"type":18},"2027-12-31",{"name":120,"class":121},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":131,"sex":15,"minAge":102,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":122},"100442434","wet-heparinized-suction-for-abdominal-cancer-100442434","NCT05041335","Wet Heparinized Suction for Abdominal Cancer","Wet Heparinized Suction: A Novel Technique to Enhance Tissue Acquisition for Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB) of Solid Abdominal Masses: A Randomized Prospective Trial","EUS Heparin","Inclusion Criteria:\n\n* Age ≥ 18 year\n* Non-pregnant Patients\n* Patients with the presence of a solid abdominal mass as seen on diagnostic imaging \\[ie. ultrasound (US), computer tomography (CT) or magnetic resonance imaging (MRI)\\] scheduled to undergo EUS examination OR Patients who underwent a prior EUS-FNA\u002FFNB for solid pancreatic mass and did not receive a conclusive diagnosis\n* Patients with platelet count \\> 50,000\n* Patients with International Normalized Ratio (INR) \\\u003C 1.5\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant Patients\n* Patients who cannot consent for themselves\n* Patients with anticoagulants or anti-platelet agents (excluding aspirin) within the last 7-10 days\n* Patients with cystic abdominal masses\n* Patients with a platelet count \\\u003C 50,000\n* Patients with an INR \\> 1.5\n* Patients with a heparin or porcine allergy\n* Patients with prior heparin induced thrombocytopenia (HIT)\n* Patient's with religious aversion to porcine-containing products",true,{"count":133,"type":18},42,"INTERVENTIONAL",[136],"NA","The purpose of this research is to compare the amount and quality of tissue obtained by EUS-FNB when the device is flushed with an anticoagulant or \"blood thinner\" vs. saline a salt water solution as well as the use of a microsieve in order for the doctor to look at the tissue to check the acceptability of the specimens before sending for analysis.\n\nYou will be randomly assigned (like a flip of a coin) to have either the blood thinner or the salt water solution placed within the needle being used to sample your abdominal tumor and to have either a sieve used or not.\n\nYou will be one of 42 participants enrolled in this data collection study which includes 1 sites in the United States.",[25,27,31,26,24],[78,140,141,142,143,144,145,146,109,147],"esophagus","stomach","gastric","pancreas","biliary","bile","bile duct","hepatic","NOT_YET_RECRUITING","2025-04-21",{"date":151,"type":86},"2025-04-22",{"date":153,"type":18},"2026-03-15",{"date":155,"type":18},"2027-01-12",{"name":157,"class":121},"H. Lee Moffitt Cancer Center and Research Institute"]